Clinical Applications of Advanced MRI and PET Techniques in Glioblastoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 1 October 2024 | Viewed by 74
Special Issue Editors
Interests: neuro-oncology; brain tumors; magnetic resonance imaging; positron emission tomography
Special Issue Information
Dear Colleagues,
Glioblastomas are infiltrating tumors in nature and extend beyond visual borders on conventional imaging. This makes complete resection of glioblastomas virtually impossible. Treatment resistance to adjuvant radiotherapy and chemotherapy lead to inevitable recurrence, and thus also contribute to the dismal prognosis of glioblastomas.
Imaging plays a pivotal role in the entire clinical pathway of glioblastomas, from diagnosis to
treatment evaluation. Conventional Magnectic Resonance Imaging (MRI) is currently the gold standard in neuro-imaging for glioblastomas. However, conventional MRI has several limitations, given it mainly demonstrates anatomical relations and is non-specific. An important clinical limitation is the inability to reliably differentiate tumor recurrence from treatment-induced changes (pseudoprogression).
To overcome the limitations of conventional MRI, more advanced MRI sequences and Positron Emission Tomography (PET) techniques have been introduced in recent years. The rationale behind advanced MRI and PET is a better visualization of biological processes, such as cellularity (diffusion MRI), neovascularization (perfusion MRI), and cellular proliferation (MR spectroscopy and PET). The utilization of advanced imaging techniques in glioblastoma can have various clinical applications, such as non-invasively establishing an accurate diagnosis and providing a prognosis or better treatment response assessment. Moreover, advanced imaging can aid affiliated clinicians in providing better treatment planning, e.g., radiotherapy or neurosurgery.
This Special Issue will provide an overview of the clinical applications of advanced MRI and PET techniques in glioblastoma.
Dr. Bart R.J. Van Dijken
Dr. Anouk Van der Hoorn
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioblastoma
- imaging
- neuroradiology
- MRI
- PET
- neurosurgery
- radiotherapy
- treatment response assessment
